174 related articles for article (PubMed ID: 31908039)
1. Deficiency of core fucosylation activates cellular signaling dependent on FLT3 expression in a Ba/F3 cell system.
Duan C; Fukuda T; Isaji T; Qi F; Yang J; Wang Y; Takahashi S; Gu J
FASEB J; 2020 Feb; 34(2):3239-3252. PubMed ID: 31908039
[TBL] [Abstract][Full Text] [Related]
2. FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia.
Kazi JU; Rönnstrand L
Mol Oncol; 2013 Jun; 7(3):402-18. PubMed ID: 23246379
[TBL] [Abstract][Full Text] [Related]
3. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).
Murata K; Kumagai H; Kawashima T; Tamitsu K; Irie M; Nakajima H; Suzu S; Shibuya M; Kamihira S; Nosaka T; Asano S; Kitamura T
J Biol Chem; 2003 Aug; 278(35):32892-8. PubMed ID: 12815052
[TBL] [Abstract][Full Text] [Related]
4. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
[TBL] [Abstract][Full Text] [Related]
5. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
Marhäll A; Heidel F; Fischer T; Rönnstrand L
Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
[TBL] [Abstract][Full Text] [Related]
6. Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication.
Natarajan K; Xie Y; Burcu M; Linn DE; Qiu Y; Baer MR
PLoS One; 2013; 8(9):e74653. PubMed ID: 24040307
[TBL] [Abstract][Full Text] [Related]
7. FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia.
Chougule RA; Kazi JU; Rönnstrand L
Oncotarget; 2016 Mar; 7(9):9964-74. PubMed ID: 26848862
[TBL] [Abstract][Full Text] [Related]
8. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
[TBL] [Abstract][Full Text] [Related]
9. Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance.
Fleischmann M; Fischer M; Schnetzke U; Fortner C; Kirkpatrick J; Heidel FH; Hochhaus A; Scholl S
Cells; 2021 Nov; 10(11):. PubMed ID: 34831215
[TBL] [Abstract][Full Text] [Related]
10. Phosphoproteome analyses reveal specific implications of Hcls1, p21-activated kinase 1 and Ezrin in proliferation of a myeloid progenitor cell line downstream of wild-type and ITD mutant Fms-like tyrosine kinase 3 receptors.
Habif G; Grasset MF; Kieffer-Jaquinod S; Kuhn L; Mouchiroud G; Gobert-Gosse S
J Proteomics; 2013 Jan; 78():231-44. PubMed ID: 23017497
[TBL] [Abstract][Full Text] [Related]
11. FLT3-ITD transduces autonomous growth signals during its biosynthetic trafficking in acute myelogenous leukemia cells.
Yamawaki K; Shiina I; Murata T; Tateyama S; Maekawa Y; Niwa M; Shimonaka M; Okamoto K; Suzuki T; Nishida T; Abe R; Obata Y
Sci Rep; 2021 Nov; 11(1):22678. PubMed ID: 34811450
[TBL] [Abstract][Full Text] [Related]
12. Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.
Reindl C; Bagrintseva K; Vempati S; Schnittger S; Ellwart JW; Wenig K; Hopfner KP; Hiddemann W; Spiekermann K
Blood; 2006 May; 107(9):3700-7. PubMed ID: 16410449
[TBL] [Abstract][Full Text] [Related]
13. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
[TBL] [Abstract][Full Text] [Related]
14. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
Nishioka C; Ikezoe T; Yang J; Takeuchi S; Koeffler HP; Yokoyama A
Leuk Res; 2008 Sep; 32(9):1382-92. PubMed ID: 18394702
[TBL] [Abstract][Full Text] [Related]
15. Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia.
Hu X; Chen F
Hematology; 2019 Dec; 24(1):651-660. PubMed ID: 31533545
[No Abstract] [Full Text] [Related]
16. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.
Choudhary C; Schwäble J; Brandts C; Tickenbrock L; Sargin B; Kindler T; Fischer T; Berdel WE; Müller-Tidow C; Serve H
Blood; 2005 Jul; 106(1):265-73. PubMed ID: 15769897
[TBL] [Abstract][Full Text] [Related]
17. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T
Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
[TBL] [Abstract][Full Text] [Related]
18. ABL2 suppresses FLT3-ITD-induced cell proliferation through negative regulation of AKT signaling.
Kazi JU; Rupar K; Marhäll A; Moharram SA; Khanum F; Shah K; Gazi M; Nagaraj SR; Sun J; Chougule RA; Rönnstrand L
Oncotarget; 2017 Feb; 8(7):12194-12202. PubMed ID: 28086240
[TBL] [Abstract][Full Text] [Related]
19. Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts.
Jacobi A; Thieme S; Lehmann R; Ugarte F; Malech HL; Koch S; Thiede C; Müller K; Bornhäuser M; Ryser M; Brenner S
Exp Hematol; 2010 Mar; 38(3):180-90. PubMed ID: 20035824
[TBL] [Abstract][Full Text] [Related]
20. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.
Yoshimoto G; Miyamoto T; Jabbarzadeh-Tabrizi S; Iino T; Rocnik JL; Kikushige Y; Mori Y; Shima T; Iwasaki H; Takenaka K; Nagafuji K; Mizuno S; Niiro H; Gilliland GD; Akashi K
Blood; 2009 Dec; 114(24):5034-43. PubMed ID: 19808698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]